Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference



    FRANKLIN, Mass., Oct. 2 /CNW/ -- Echo Therapeutics, Inc. (OTC Bulletin
Board: ECTE) announced today that Patrick T. Mooney, M.D., Chairman and Chief
Executive Officer, will present at the JMP Securities Healthcare Investor
Conference on October 7, 2008 at 10:00 am Eastern Standard Time.  The
presentation will occur live and will be held at Le Parker Meridien Hotel in
New York City.
    
    About Echo Therapeutics
    
    Echo Therapeutics is focused on transdermal medical devices and specialty
pharmaceuticals. Echo's Symphony(TM) tCGM System is in late-stage development
as a non-invasive (needle-free), wireless, transdermal continuous glucose
monitoring (tCGM) system for patients with Type 1 and Type 2 diabetes and for
use in hospital critical care units. Echo's AzoneTS reformulation technology
is focused on building a pipeline of safer and improved versions of widely-
prescribed, FDA-approved specialty pharmaceutical products. Echo's Symphony
tCGM System consists of its wireless transmission and transdermal biosensor
technologies and its Prelude(TM) SkinPrep System, which incorporates leading-
edge, needle-free skin permeation control. Echo expects the Symphony tCGM
System to provide both diabetics and hospital professionals with a reliable,
affordable, comfortable-to-wear, and easy-to-use, needle-free continuous
glucose monitoring device.
    
    Forward-Looking Statements
    
    This press release contains forward-looking information that involves
risks and uncertainties, including statements regarding Echo's development
plans, objectives, expectations and intentions, including, without limitation,
statements regarding the Company's Symphony tCGM System and AzoneTS product
candidates. Factors that could adversely affect Echo's business and prospects
are described in the Company's filings with the Securities and Exchange
Commission. Echo expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect any change
in the Company's expectations or any change in events, conditions or
circumstances on which any such statement is based.

    
    Investor Relations Contacts:
    

    
    Patrick T. Mooney, M.D.
    Chairman & CEO
    Echo Therapeutics
    508-530-0329
    

    
    Lilian Stern
    Stern Investor Relations
    212-362-1200

    




For further information:

For further information: Investors, Patrick T. Mooney, M.D., Chairman &
CEO of Echo Therapeutics, +1-508-530-0329, or Lilian Stern of Stern Investor
Relations, +1-212-362-1200 Web Site: http://www.echotx.com

Organization Profile

ECHO THERAPEUTICS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890